Humana Just Ripped 48% in a Month. Is It Outperforming Other Healthcare Stocks Like UnitedHealth and Cigna?

Shares of Humana (NYSE:HUM | HUM Price Prediction) are trading near $303 at midday Monday, slightly lower on the session after a flat open. The one-month picture, however, tells a very different story. Humana stock is up 48% over the past month, dwarfing peers in the managed care complex.

That run has put Humana well ahead of UnitedHealth Group (NYSE:UNH), up 19% over the same stretch, and Cigna Group (NYSE:CI), up just 2.5%. The performance gap is striking for three companies that occupy overlapping corners of the same industry.

So is Humana genuinely outperforming, or just snapping back from a deep multi-year drawdown? The short answer is yes, HUM stock is leading the pack by a meaningful margin. The longer answer is more nuanced.

Medicare Advantage Tailwind Drives the Rally

Humana’s surge reflects a stack of catalysts centered on Medicare Advantage (MA). A favorable MA rate decision earlier this year lifted a major regulatory overhang, and Humana’s concentrated MA exposure means it benefits more than diversified peers. Bernstein recently raised its price target on the stock to $288 from $211, citing improved MA final rates and positive Q1 utilization signals.

The company’s Q1 2026 results reinforced the recovery narrative. Humana’s adjusted EPS of $10.31 beat the $10.20 consensus, while revenue rose 24% year over year (YoY) to $39.65 billion. The insurance segment benefit ratio of 89% landed favorable to internal guidance.

Management affirmed FY2026 adjusted EPS guidance of at least $9 and revenue of at least $160 billion. Humana CEO Jim Rechtin stated the company has had “a solid start to the year” and feels good about how operating execution is setting Humana up for the future. Individual MA membership is up 22% year to date (YTD).

Today’s session shows the stock catching its breath. Humana opened at $301.11 and has traded a tight range between $293 and $304, suggesting consolidation rather than a fresh leg higher. Volume looks subdued versus the late-April breakout day, when HUM stock gapped up on more than four million shares.

How UNH and CI Stack Up

UnitedHealth Group posted a strong quarter of its own. Adjusted EPS of $7.23 topped the $6.61 consensus, the medical cost ratio improved to 84%, and management lifted FY2026 adjusted EPS guidance to greater than $18.25. UNH’s diversified mix across Optum and employer plans dilutes the MA tailwind powering Humana.

Cigna Group is the laggard of the trio. Cigna’s Q1 2026 adjusted EPS of $7.79 marked a fourth consecutive beat, and revenue grew 5% to $68.49 billion, with the medical care ratio improving to 80%. Cigna’s business mix tilts toward commercial insurance and the Express Scripts pharmacy benefit manager (PBM), leaving it less levered to the MA rate cycle.

The peer scorecard fills in further on longer timeframes. Humana stock is up 18.5% YTD, close to UnitedHealth stock’s 17% gain, while Cigna stock has added just 4%. Over one year, however, UNH actually leads the trio at 33%, with HUM up 28% and Cigna in negative territory.

Bull Case vs. Bear Case

The bull case for Humana stock starts with margin recovery runway. The October Stars ratings release sits as a near-term catalyst, the MaxHealth acquisition closed in February, and operating cash flow surged 279% YoY in Q1 2026 to $1.254 billion. Margin stabilization across managed care reinforces the thesis.

The bear case is that most of the regulatory relief now looks priced in. Trefis suggested Humana stock may be overvalued by 16% against a fair value near $212.87. Morgan Stanley kept an Underweight rating despite lifting its target to $217 from $146.

The long-term context matters here. Humana stock is still down 32% over the past five years, so the past month reads more as a recovery rally than the start of a fresh bull market. The chart is rebuilding, not breaking out.

What to Watch

Keep an eye on whether Humana stock holds the $300 zone into next month’s enrollment commentary and the October Star Ratings release. The pace of the rally suggests much of the regulatory relief is already in the price. Future upside likely depends on execution rather than another sentiment swing.

Prudent investors weighing fresh exposure may want to size positions modestly given how fast HUM stock has moved. The Q1 2026 beat and affirmed guidance support the story, but the valuation has caught up quickly. The next concrete data points come from the Star Ratings cycle and FY2026 quarterly progression.